Literature DB >> 27789679

Carboxy-terminal fragment of fibroblast growth factor 23 induces heart hypertrophy in sickle cell disease.

Marie Courbebaisse1,2,3,4, Hind Mehel2, Camille Petit-Hoang2, Jean-Antoine Ribeil5, Laurent Sabbah6, Véronique Tuloup-Minguez2, David Bergerat2, Jean-Benoit Arlet7,8, Aurélie Stanislas5, Jean-Claude Souberbielle2,3, Hervé Le Clésiau9, Rodolphe Fischmeister10, Gérard Friedlander1,2,4, Dominique Prié11,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27789679      PMCID： PMC5286949          DOI： 10.3324/haematol.2016.150987

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

Review 1.  Sickle-cell disease and the heart: review of the current literature.

Authors:  Ersi Voskaridou; Dimitrios Christoulas; Evangelos Terpos
Journal:  Br J Haematol       Date:  2012-04-25       Impact factor: 6.998

2.  FGF23 induces left ventricular hypertrophy.

Authors:  Christian Faul; Ansel P Amaral; Behzad Oskouei; Ming-Chang Hu; Alexis Sloan; Tamara Isakova; Orlando M Gutiérrez; Robier Aguillon-Prada; Joy Lincoln; Joshua M Hare; Peter Mundel; Azorides Morales; Julia Scialla; Michael Fischer; Elsayed Z Soliman; Jing Chen; Alan S Go; Sylvia E Rosas; Lisa Nessel; Raymond R Townsend; Harold I Feldman; Martin St John Sutton; Akinlolu Ojo; Crystal Gadegbeku; Giovana Seno Di Marco; Stefan Reuter; Dominik Kentrup; Klaus Tiemann; Marcus Brand; Joseph A Hill; Orson W Moe; Makoto Kuro-O; John W Kusek; Martin G Keane; Myles Wolf
Journal:  J Clin Invest       Date:  2011-10-10       Impact factor: 14.808

3.  Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor.

Authors:  Regina Goetz; Mutsuko Ohnishi; Serkan Kir; Hiroshi Kurosu; Lei Wang; Johanne Pastor; Jinghong Ma; Weiming Gai; Makoto Kuro-o; Mohammed S Razzaque; Moosa Mohammadi
Journal:  J Biol Chem       Date:  2012-06-25       Impact factor: 5.157

Review 4.  Fibroblast growth factor 23 and the heart.

Authors:  Christian Faul
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-07       Impact factor: 2.894

5.  Fibroblast Growth Factor 23 and Cause-Specific Mortality in the General Population: The Northern Manhattan Study.

Authors:  Nao Souma; Tamara Isakova; David Lipiszko; Ralph L Sacco; Mitchell S V Elkind; Janet T DeRosa; Shonni J Silverberg; Armando J Mendez; Chuanhui Dong; Clinton B Wright; Myles Wolf
Journal:  J Clin Endocrinol Metab       Date:  2016-08-08       Impact factor: 5.958

6.  Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice.

Authors:  Erica L Clinkenbeard; Emily G Farrow; Lelia J Summers; Taryn A Cass; Jessica L Roberts; Christine A Bayt; Tim Lahm; Marjorie Albrecht; Matthew R Allen; Munro Peacock; Kenneth E White
Journal:  J Bone Miner Res       Date:  2014-02       Impact factor: 6.741

7.  Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.

Authors:  Myles Wolf; Todd A Koch; David B Bregman
Journal:  J Bone Miner Res       Date:  2013-08       Impact factor: 6.741

Review 8.  Latest findings in phosphate homeostasis.

Authors:  Dominique Prié; Pablo Ureña Torres; Gérard Friedlander
Journal:  Kidney Int       Date:  2009-02-04       Impact factor: 10.612

9.  FGF23 is correlated with iron status but not with inflammation and decreases after iron supplementation: a supplementation study.

Authors:  Vickie Braithwaite; Andrew M Prentice; Conor Doherty; Ann Prentice
Journal:  Int J Pediatr Endocrinol       Date:  2012-10-26

10.  The hypoxia-inducible factor-1α activates ectopic production of fibroblast growth factor 23 in tumor-induced osteomalacia.

Authors:  Qian Zhang; Michele Doucet; Ryan E Tomlinson; Xiaobin Han; L Darryl Quarles; Michael T Collins; Thomas L Clemens
Journal:  Bone Res       Date:  2016-07-05       Impact factor: 13.567
View more
  5 in total

Review 1.  Biology of Fibroblast Growth Factor 23: From Physiology to Pathology.

Authors:  Marie Courbebaisse; Beate Lanske
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

2.  Effects of erythropoietin on fibroblast growth factor 23 in mice and humans.

Authors:  Mark R Hanudel; Michele F Eisenga; Maxime Rappaport; Kristine Chua; Bo Qiao; Grace Jung; Victoria Gabayan; Barbara Gales; Georgina Ramos; Maarten A de Jong; Jelmer J van Zanden; Martin H de Borst; Stephan J L Bakker; Elizabeta Nemeth; Isidro B Salusky; Carlo A J M Gaillard; Tomas Ganz
Journal:  Nephrol Dial Transplant       Date:  2019-12-01       Impact factor: 5.992

Review 3.  Skeletal endocrinology: where evolutionary advantage meets disease.

Authors:  Nikolai Jaschke; Wolfgang Sipos; Lorenz C Hofbauer; Tilman D Rachner; Martina Rauner
Journal:  Bone Res       Date:  2021-05-28       Impact factor: 13.567

4.  Plasma total fibroblast growth factor 23 levels are associated with acute kidney injury and mortality in children with acute respiratory distress syndrome.

Authors:  Mark R Hanudel; Matthew S Zinter; Lucia Chen; Kinisha Gala; Michelle Lim; Mona Guglielmo; Tanaya Deshmukh; Sitaram Vangala; Michael Matthay; Anil Sapru
Journal:  PLoS One       Date:  2019-09-05       Impact factor: 3.240

5.  Epoetin Beta and C-Terminal Fibroblast Growth Factor 23 in Patients With Chronic Heart Failure and Chronic Kidney Disease.

Authors:  Michele F Eisenga; Mireille E Emans; Karien van der Putten; Maarten J Cramer; Adry Diepenbroek; Birgitta K Velthuis; Pieter A Doevendans; Marianne C Verhaar; Jaap A Joles; Stephan J L Bakker; Ilja M Nolte; Branko Braam; Carlo A J M Gaillard
Journal:  J Am Heart Assoc       Date:  2019-08-17       Impact factor: 5.501
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.